CAR-T cells take on progressive MS: early trial launches
NCT ID NCT06675864
First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This early-phase trial tests a single dose of YTB323, a CAR-T cell therapy, in 28 adults with non-active progressive multiple sclerosis. The study aims to check safety and track disability changes over time. Participants must be 18–60 and able to undergo lumbar punctures and MRIs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YTB323 (rapcabtagene autoleucel), a CAR-T cell therapy
What this could lead to
If it works, this could point toward a new way to slow or stop disability worsening in progressive multiple sclerosis.
What could go wrong
This is an early phase 1/2 study with only 28 participants, so results may not apply broadly. CAR-T therapies carry risks like cytokine release syndrome and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
-
Novartis Investigative Site
RECRUITINGMelbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
RECRUITINGQuébec, Quebec, G1J 1Z4, Canada
-
Novartis Investigative Site
RECRUITINGBron, 69677, France
-
Novartis Investigative Site
RECRUITINGMontpellier, 34090, France
-
Novartis Investigative Site
RECRUITINGNancy, 54035, France
-
Novartis Investigative Site
RECRUITINGRennes, 35033, France
-
Novartis Investigative Site
RECRUITINGEssen, 45147, Germany
-
Novartis Investigative Site
RECRUITINGMainz, 55131, Germany
-
Novartis Investigative Site
RECRUITINGUlm, 89081, Germany
-
Novartis Investigative Site
RECRUITINGGenova, GE, 16132, Italy
-
Novartis Investigative Site
RECRUITINGMilan, MI, 20132, Italy
-
Novartis Investigative Site
RECRUITINGBarcelona, 08035, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28222, Spain
-
Novartis Investigative Site
RECRUITINGMálaga, 29010, Spain
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGBern, 3010, Switzerland
-
Novartis Investigative Site
RECRUITINGLausanne, 1011, Switzerland
-
Novartis Investigative Site
RECRUITINGZurich, 8091, Switzerland